Sanxin Medtec(SZ:300453) Sou Hu Cai Jing·2025-08-11 08:16Core Viewpoint - The financial performance of Sanxin Medical (300453) shows positive growth, with significant increases in revenue and net profit, indicating a stable investment opportunity in the healthcare sector [1]. Financial Performance - As of August 11, 2025, Sanxin Medical reported a total revenue of 761 million yuan, representing a year-on-year growth of 10.83% [1]. - The net profit attributable to shareholders reached 115 million yuan, with a year-on-year increase of 8.35% [1]. - The company's non-recurring net profit was 103 million yuan, reflecting a growth of 9.26% year-on-year [1]. - Key financial ratios include a current ratio of 1.473, a quick ratio of 1.106, and a debt-to-asset ratio of 36.16% [1]. Market Activity - The stock price of Sanxin Medical closed at 9.41 yuan, up by 3.98%, with a turnover rate of 7.28% and a trading volume of 259,900 hands, amounting to a transaction value of 241 million yuan [1]. - The net inflow of main funds was 24.72 million yuan, accounting for 10.27% of the transaction value [1]. - Large orders saw a net inflow of 30.79 million yuan, while small orders experienced a net outflow of 30.11 million yuan [1]. Company Background - Sanxin Medical, established in 1997 and located in Nanchang, is primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of approximately 5.22 billion yuan and a paid-in capital of about 542 million yuan [1]. - The legal representative of the company is Peng Yixing [1]. Investment and Intellectual Property - Sanxin Medical has made investments in 14 enterprises and participated in 783 bidding projects [2]. - The company holds 46 trademark registrations and 212 patents, along with 175 administrative licenses [2].